Topline data were announced from two phase 3 trials evaluating oveporexton in patients with narcolepsy type 1.

Second Quarter Revenues of $390.7 Million - - GAAP Net Income of $87.1 Million and Diluted GAAP Earnings per Share of $0.52 - - Company Reiterates 2025 Financial Expectations ...

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is one of the 13 Best Low Risk High Growth Stocks to Buy. Mixed analysts’ ...

Some non-ADHD students misuse stimulants like Ritalin, risking addiction. But children with ADHD who take psychostimulants ...

Alkermes Plc (NASDAQ:ALKS), a neuroscience-focused biopharmaceutical company, released its second quarter 2025 results on July 29, 2025. The standout news was a significant outper ...

It began subtly. Anil Kumar, a 42-year-old chartered accountant from Kochi, found himself waking up at 2am most nights, ...

This week on "The Readout LOUD" podcast, a mother whose son has Duchenne muscular dystrophy shares her perspective on Sarepta ...

Key Points Shopify's moat and vast runway for growth make its prospects highly attractive. Axsome Therapeutics has a robust ...

Mindfulness-based cognitive therapy can reduce psychological distress and improve well-being of adult patients with ...

Nootropics are substances that enhance cognitive performance through various mechanisms, including cholinergic, glutamatergic ...

With the world on fire and the economy in crisis, many of us are struggling to get the recommended six to nine hours of sleep each night. However, a rare condition causes some to doze for nearly ...

Comprehensive review of broad pipeline targeting Alzheimer’s disease agitation, depression, narcolepsy, fibromyalgia, ADHD, ...